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Abstract
The optimal revascularization strategy for patients with multi-vessel coronary artery
disease remains controversial. The advent of percutaneous coronary intervention
(PCI) has challenged the superiority of coronary artery bypass graft (CABG) surgery
for multi-vessel disease. In the late 1990s, an integrated approach, now referred to as
“hybrid coronary revascularization” (HCR), was pioneered combining CABG and
PCI to offer appropriate patients a less invasive option for revascularization while still
capitalizing on the superior patency rates of the left internal mammary artery (LIMA)
to the left anterior descending (LAD) artery bypass . The operative techniques
continue to evolve as well as the timing strategies for intervention and use of anti-
platelet therapy. While more research is needed, current data supports hybrid
coronary revascularization as a promising technique to optimize outcomes in patients
with multi-vessel coronary artery disease.
Keywords: Hybrid Coronary Revascularization, Coronary Artery Disease, Coro‐
nary Artery Bypass Grafting, Percutaneous Coronary Intervention, Robotics
1. Introduction
The optimal revascularization strategy for patients with multi-vessel coronary artery disease
remains controversial. The advent of percutaneous coronary intervention (PCI) has challenged
the superiority of coronary artery bypass graft (CABG) surgery for multi-vessel disease as PCI
offers a less invasive option with faster recovery time and lower risk. Despite a survival benefit
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in high-risk groups and superior long-term freedom from revascularization, trends continue
to move toward increasing percutaneous approaches. In the late 1990s, an integrated approach,
now referred to as “hybrid coronary revascularization” (HCR), was pioneered combining
CABG and PCI to offer appropriate patients a less invasive option for revascularization while
still capitalizing on the superior patency rates of the left internal mammary artery (LIMA) to
left anterior descending (LAD) artery bypass. The technology has evolved tremendously since
the introduction of HCR with some LIMA-LAD grafts now performed completely robotically.
As HCR evolves, questions regarding indications, optimal surgical technique, timing, and
outcomes as well as cost-benefit analysis continue to permeate current practice and will define
the future of HCR in the algorithm of coronary revascularization.
2. Rationale
CABG has long been the established standard of care to treat left main or three vessel coronary
artery disease [1]. The therapeutic benefit of this approach lies in the LIMA-LAD revasculari‐
zation. Patency rates of this anastomosis lie between 95%–98% at 10 years [2]. Radial arterial
conduits have been explored as another option for total arterial revascularization; however,
results do not compare with the long-term patency of LIMA utilization [3]. Saphenous vein
grafts (SVG) also do not provide the same longevity of the LIMA-LAD revascularization.
Failure of SVG is multifactorial including technical failure within 30 days, neo-intimal
hyperplasia at 1–24 months, and atherosclerotic degeneration beyond 2 years. Patient risk
factors such as hyperlipidemia and ongoing tobacco are also associated with accelerated graft
failure. Failure rates are estimated as high as 10%–15% at 1 year after CABG with almost 50%
total graft occlusion at 10 years [4]. Despite this high failure rate, SVG remain the most
commonly used conduit for CABG surgery.
PCI has challenged the superiority of CABG surgery for multi-vessel disease. The use of drug-
eluting stents (DES) in particular has provided a less invasive option for revascularization with
faster return to normal activities and lower risk of complications. Restenosis rates and stent
thrombosis of DES in non-LAD lesions are markedly lower than non-LAD SVG with rates less
than 10% and 1%, respectively [5]. In addition, stenting of SVG after thrombosis introduces
technical changes with higher peri-procedural rates of complications and in-hospital mortality
than stenting of native arteries [4, 6]. Despite data that suggests improved outcomes with many
patients including diabetics and those with left main and complex multi-vessel coronary artery
disease (CAD) [2], trends continue toward increased PCI over CABG.
The strategy of HCR attempts to capitalize on the superior LIMA-LAD patency rates as well
as the minimally invasive PCI approach thus eliminating the need for additional venous or
arterial conduits. Patients with multi-vessel disease with significant proximal LAD disease
with other lesions suitable for PCI in the left main, left circumflex, or right coronary artery
territories are appropriate candidates for HCR [7]. In addition, patients with lack of suitable
conduits, prior sternotomy, severe ascending aortic disease, or coronary arteries not amenable
for bypass may be suitable HCR candidates. Patients generally not deemed HCR candidates
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and thus deferred to conventional CABG include those with chronic total occlusions, highly
calcified segments, and diffusely diseased and bifurcation coronary lesions [7]. Table 1
summarizes the clinical and angiographic findings that should be taken into consideration
when discussing the option for HCR. Discussions regarding treatment options are best
facilitated by a multi-disciplinary approach including both an interventional cardiologist and
cardiac surgeon.
PCI CABG HCR
Angiographic Characteristics
Unprotected Left Main Disease no yes yes
Intra-myocardial LAD yes no no
Complex LAD lesion no yes yes
Complex non-LAD lesions no yes no
Comorbidities
Advanced Age yes no yes
LVEF <30% no yes yes
Diabetes mellitus no yes yes
Renal insufficiency no yes yes
Severe chronic lung disease yes no no
Prior left thoracotomy yes yes no
Prior sternotomy yes no yes
Limited vascular access no yes no
Lack of available conduits yes no yes
Severe aortic calcification yes no yes
Contraindication for dual
anti-platelet therapy
no yes no
Table 1. Recommendations for Candidates for Hybrid Coronary Revascularization Versus Conventional Coronary
Revascularization [2, 21]
3. Strategies and surgical approach
3.1. Surgical approaches
Minimally invasive cardiac surgery seeks to eliminate two invasive components of conven‐
tional CABG: cardiopulmonary bypass (CBP) and sternotomy. The development of stabilizer
technology in the early 1990s made available off-pump CABG with the potential advantages
of less blood loss, lower incidence of neurologic complications, and less pulmonary compli‐
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cations [8]. In conjunction with sternal sparing incisions as well as robotic techniques, a
minimally invasive off-pump option for LIMA-LAD revascularization offers the key to
optimizing the HCR option. The techniques described below and in Table 2 discuss the current
options for minimally invasive surgical approaches to LIMA-LAD revascularization high‐
lighting key features of the various techniques.
Thoracic Access LIMAHarvest Anastomosis
Single Lung
ventilation CPB Advantages/Disadvantages
OPCAB
(Off-pump CABG)
Midline
Sternotomy
Direct
Vision
Direct vision
with
stabilizers
Not Required No Avoids risks associatedwith CBP
MIDCAB
(Minimally invasive
direct
coronary artery bypass
grafting)
Left-sided
thoracotomy
or lower partial
sternotomy
Direct
Vision Direct Vision
Improves
exposure but
not required
Not required but
can be performed
by femoral
cannulation
Avoids aortic cross-
clamping and manipulation
Endo-ACAB
(Endoscopic atraumatic
coronary
artery bypass graft
surgery)
Limited rib sparing
left-sided
thoracotomy
Robotic or
Thoracosco
pic
Hand-
Sutured
Required when
robot
is used
Not required
Decreased morbidity from
thoracotomy incision yet
allows for hand-sewn
anastomosis
TECAB
(Totally endoscopic
coronary
artery bypass graft
surgery)
Thoracoscopic Robotic
Robotic
intracorpore
al
anastomosis
Required Not required
Minimally invasive,
however very technically
challenging
Table 2. Surgical Techniques Used for LAD Revascularization During Hybrid Coronary Revascularization
MIDCAB: Minimally invasive direct coronary artery bypass(MIDCAB) grafting refers to an
off-pump minimally invasive LIMA-LAD revascularization performed through a small left-
sided thoracotomy in the fourth or fifth interspace. Costal cartilage removal or rib disarticu‐
lation is sometimes necessary for visualizing. Cardiac stabilization and LAD harvest is
performed directly through the wound and does not require endoscopic or robotic skills to
master the LAD harvest. Surgeon comfort with off-pump techniques is critical as well as
experience with sternal sparing incisions. Single-lung ventilation is optimal for exposure;
however chest cavity insufflation is not necessary. A slightly larger thoracotomy incision can
allow exposure for harvest of bilateral internal mammary arteries.
Large series published since 1994 have validated short-term LAD-LIMA patency rates of this
technique at 95%–97% [8]. The advantage of this technique lies in the avoidance of CBP and
aortic manipulation as an off-pump strategy; however, no data exists to suggest differences in
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post-operative pain or pulmonary complications from conventional CABG [8]. MIDCAB may
have decreased bleeding and infection rates compared to traditional sternotomy, however the
need for a thoracotomy incision for the technique has prompted further exploration into
various thoracoscopic and robotic techniques to capitalize on the advantages of minimally
invasive strategies as discussed in the following.
Endo-ACAB: Endoscopic atraumatic coronary artery bypass (Endo-ACAB) refers to the
thoracosocpic or robotic identification of the LAD with LIMA mobilization without violating
the integrity of the chest wall (Figure 1). A directed, non-rib spreading or limited rib spreading
thoracotomy is then employed for a hand-sewn LIMA-LAD anastomosis on the beating heart.
Robotic LIMA mobilization requires single-lung ventilation and insufflation to create space in
the anterior mediastinum to facilitate LIMA harvest. After the LIMA is taken down, a peri‐
cardial incision is made for identification of the LAD. A small (4–5cm) anterior thoracotomy
without disarticulation of costal cartilage is then made to introduce an endoscopic stabilizer
via an arm port, which allows for LAD stabilization and hand-sewn anastomosis.
Figure 1. EndoCab technique as described above.
Multiple case series have reported excellent LIMA-LAD patency rates with thoracoscopic
Endo-ACAB approaches. In new smaller series with robotic Endo-ACAB approaches, routine
post-operative angiography has demonstrated no decline in LIMA-LAD patency rates. In
Kiaii’s series of 58 patients who underwent one-stage robotic Endo-ACAB HCR, the average
length of stay in the ICU and hospital were 1 and 4 days, respectively, leading the authors to
suggest benefit to patients in terms of post-operative surgical morbidity and recovery time
using more minimally invasive technology [9].
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TECAB: Totally endoscopic coronary artery bypass grafting (TECAB) utilizes a robotically
sewn, intracorporeal anastomosis, which negates the need for even a small thoracotomy. This
technique was first explored on an arrested heart during CBP; however, the associated
complications of CPB have led most robotic surgeons to employ an off-pump TECAB. The
operation itself is technically challenging without widespread adoption of this technique
owning to the need for robotic technology and surgeon expertise.
One of the largest series published in 2012 reported on 226 patients with 5-year outcomes [10].
Perioperative results were consistent with the standards of open CABG. The authors report a
dramatically decreased time to recovery owning to the lack of need for sternal precautions. In
the 10 cases requiring conversion to thoracotomy, these patients averaged 2- day longer
hospital stays with increased ventilator time and return to normal activities [10]. Overall results
in other case series support the safety and feasibility of this technique; however, Harskamp
reports that only approximately one-third of HCRs from 2011–2013 reported in the Society of
Thoracic Adult Cardiac Database utilize robotic technology [11]. Expansion of the TECAB
approach is currently limited by the cost and learning curve associated with the implementa‐
tion of robotic technology.
Graft Assessment: Off-pump (OP) and minimally invasive techniques for LAD-LIMA grafting
have appropriately been scrutinized with regard to patency rate outcomes compared to the
classical on-pump CABG via a midline sternotomy. The recent Randomized On/Off Bypass
(ROOBY) trial as well as other smaller trails have demonstrated that the patency rates of LIMA-
LAD grafts between off-pump coronary artery bypass (OPCAB) and conventional CABG were
similar (95.3 and 96.2, respectively) [12]. As the HCR approach relies upon the durability and
integrity of this anastomosis, the ability of the surgeon to assess the LIMA-LAD graft intra-
operatively becomes increasingly important. In fact, the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery (EACTS) recommends graft
evaluation before leaving the operating room [13].
Graft assessment includes the traditional methods such as inspection, palpation, electrocar‐
diography (ECG), and echocardiography (ECHO). Other methods include conventional
coronary angiography, which is the gold standard, transit-time flow measurement (TTFM),
and intra-operative fluorescence imaging (IFI). As the causes of early graft failure are often
technical, this technology seeks to eliminate these errors by objectively evaluating graft
function. Certainly, a clear advantage of single stage HCR with CABG followed by PCI lies in
the opportunity for angiographic graft assessment with readily available operative access for
reintervention; however, when angiographic assessment is not available, the most commonly
utilized technique among cardiovascular surgeons over the last decade has become TTFM.
Retrospective studies have demonstrated the ability of TTFM to detect grafts with impaired
flow thus predicting graft failure within 6 months after CABG [14]; however, little is known
about how TTFM relates to long-term graft patency and patient survival.
TTFM relies on the principles of transit-time ultrasound technology. The surgeon can obtain
both quantitative data of average blood flow volume and several calculated derivatives of the
flow of blood in the graft displayed in waveform. TTFM cannot, however, differentiate
physiologic conditions accounting for low blood flow versus technical quality of a surgical
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anastomosis. While clear cut-off values for graft revision have not been set, a mean flow <15ml
min -1 for grafts to the left coronary system and less than 20ml min -1 for grafts to the right
coronary system were predictive of failure. A pulsatility index (PI) greater than 0.5 is predictive
of graft failure. Another important value is the diastolic flow percentage (DF%) or diastolic
flow divided by total flow through the graft. This value should be greater than 50% for all
grafts and territories and ideally greater than 65%. When the PI and DF% both demonstrate
adequate measurements, the graft can be objectively presumed adequate [15]. Figure 2
demonstrates the intra-operative TTFM tracings utilizing the MediStim ASA technology,
which is one of the more commonly utilized flowmeters.
Figure 2. Transit Time Flow Assessment.
3.2. Timing strategies
HCR began in the 1990s as a staged procedure with LIMA-LAD revascularization performed
first followed by PCI. The use of DESs and anti-platelet therapy as well as the use of hybrid
operating room suites has introduced questions as to the most optimal timing for open and
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PCI revascularization. Currently, three options for timing strategies exist: PCI followed by
CABG, CABG followed by PCI, and one-stage hybrid HCR. Each option introduces different
benefits and challenges, and at this time no clear consensus exists on the optimal strategy for
timing of revascularization (Table 3). Patient characteristics, operator skill, and availability of
facilities should be considered when choosing the most appropriate approach.
One-Stage HCR Two-Stage HCR
Simultaneous CABG and PCI CABG then PCI PCI then CABG
Advantages: Advantages: Advantages:
Ability to study LIMA-LAD graft Ability to study LIMA-LAD graft Pre-operative angiographic imaging of
LIMA size
Protected LAD to allow PCI to
high-risk non-LAD lesions
Protected LAD to allow PCI to
high-risk non-LAD lesions
Lower risk of ischemia during
CABG given non-LAD territory
revascularization
Single anesthetic exposure Reduced risk of post-surgical bleedingas
no need for anti-platelet therapy post
CABG
Useful in acute coronary
syndromeswith non-LAD culprits
Can convert to conventional CABG
if PCI fails
After LIMA-LAD revascularization,
asymptomatic patients may require no
further intervention
If stents unsuccessful, conventional
CABG has to be subsequently
performed
Single procedure reduces cost and
hospital length of stay
Disadvantages: Disadvantages: Disadvantages:
Requires hybrid suite Risk of ischemia during CABG in non-
LAD
lesions
No ability to angiographically evaluate
LIMA-LAD anastomosis
Increased risk of post-operative
bleeding due to need for anti-platelet
after surgery
Unsuccessful PCI may lead to need
for surgical reintervention
Increased peri-operative bleeding due
to need for anti-platelet therapy
Risk of stent thrombosis due to
post-operative inflammatory state
Potential for LAD territory ischemia
between stages
CKD patients exposed to dual
nephrotoxic insults with surgery
and PCI contrast use
Higher risk of stent thrombosis due to
inflammatory response of CABG and
potential need to hold anti-platelet
therapy
High degrees of coordination needed
between teams
Table 3. Advantages and Disadvantages of One and Two-Staged HCR Procedures
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One-Stage HCR: Simultaneous CABG and PCI: The advent of hybrid operating room suites
has introduced the option for simultaneous CABG and PCI. This approach allows for complete
revascularization before leaving the operating room. Routine imaging of the LIMA-LAD
anastomosis is also available before chest closure. More aggressive percutaneous approaches
can be taken to otherwise challenging lesions given the safety net of open revascularization
options. The patient benefits from a single anesthetic exposure and decreased hospitalization
time. One ongoing concern however is the post-operative risk of bleeding given the need for
dual anti-platelet therapy after DES placement in conjunction with incomplete heparin
reversal. Concerns also exist regarding the relationship of the inflammatory response in the
post-operative setting and risk for acute stent thrombosis.
Two-Stage: PCI Followed by CABG: This option confers several advantages. In revascula‐
rizing the non-LAD lesion first and thus providing collateralization, the potential risks of
ischemia during LAD occlusion are minimized. PCI firstly also provides the interventional
cardiologist a safety net should revascularization be unsuccessful percutaneously. The most
important benefit of this approach occurs in the setting of acute coronary syndrome with a
non-LAD culprit. The acutely affected lesion may be stented followed by LAD revasculariza‐
tion at a later time. This strategy does however introduce the difficulty of the need for anti-
platelet therapy with DES. Even brief discontinuation of anti-platelet therapy can risk stent
thrombosis; however this must be weighed with intra-operative bleeding risk. Investigation
is underway regarding the use of newer anti-platelet agents and potential decreased bleeding
risk. It again should be noted that the pro-inflammatory trauma from surgery could also put
new stents at risk for thrombosis.
Two-Stage: CABG Followed by PCI: This strategy has become the most widely adopted one
for HCR. With PCI post-CABG, the concern for surgical bleeding while on anti-platelet therapy
is negated. Like hybrid HCR, LIMA-LAD graft patency can be confirmed during PCI angiog‐
raphy. Pre-PCI protection of the LAD also provides the interventional cardiologist the option
to approach lesions that would perhaps have otherwise been at higher risk. This includes both
left main lesions and diagonal bifurcation lesions [8]. For the minimally invasive surgeon, the
unrevascularized collateral lesions could manifest as intra-operative ischemia. Careful
attention must be paid to hemodynamics during insufflation, and the use of peripheral CPB
should be considered if needed. In the scenario of a PCI complication or failure, this approach
could necessitate a return to the operating room with emergent CABG. The optimal time frame
for PCI following CABG remains unclear. Some teams opt for PCI during the index hospital‐
ization and thus avoid patient discharge with an incomplete revascularization, however other
teams propose a more extended period of waiting from 1 to several weeks. Economic factors
also become an increasing concern given questions of reimbursement.
Overall, no clear optimal timing strategy has been clearly defined. While some studies
demonstrate increased post-operative bleeding risks on dual-anti-platelet therapy, others
suggest that the minimally invasive surgical approaches negate this risk traditionally associ‐
ated with sternotomy. Harskamp’s analysis of recent STS data suggests that the need for post-
operative transfusion was actually lower in the one-stage procedure group with comparable
reoperation for bleeding [11]. This analysis also reports that patients undergoing one-stage
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procedures were more likely to have peripheral vascular disease and stroke history compared
to other groups [11]. Further studies are needed to outline the specific clinical scenarios and
patient characteristics, which should dictate the timing of CABG and PCI. Certainly, cost
analysis and patient preferences will also factor into future decision-making regarding timing
strategies.
Anti-platelet management: As discussed, the use of anti-platelet therapy is a complicated
balance of post-surgical bleeding versus risk of acute stent thrombosis. Currently, no guide‐
lines exist to define the optimal strategy. This question of anti-platelet therapy poses two
questions regarding the order of staging as well as timing of initiation of therapy. Different
authors have reported their experience with varying strategies and outcomes. In cases of two
staged procedures with CABG first, most authors performed CABG on aspirin alone followed
by a second anti-platelet agent greater than 4 h post-operatively after ensuring that there were
no bleeding complications [16]. In the two stage procedures, which performed PCI first, anti-
platelet therapy was begun before PCI and continued uninterrupted during CABG. In one-
stage procedures, the most common strategies administered anti-platelet therapy after
undergoing the LIMA-LAD graft, just before its completion, or immediately after PCI. Others
administered anti-platelet therapy at the induction of anesthesia or in the pre-operative area
owning to the fact that maximal platelet inhibition occurs 4–24 h after administration [16].
None of these strategies differed in reported rate of acute stent thrombosis [5]. In some studies,
the rate of blood transfusion was actually lower in the HCR group as was the need for
reoperation for bleeding [11]. Newer anti-platelet agents that are more potent and have a faster
onset of action and reversal have also been employed; however, there is currently no data to
support the use of these new agents in HCR.
4. Outcomes
Multiple case series from single institution experiences have been published on HCR since
the first report in 1996. This includes a population of over 3,000 patients [16]. Data from
these  series  suggest  that  in  experienced  hands,  the  safety  profile  of  HCR  is  excellent.
Multiple  studies  comparing outcomes after  HCR versus CABG and multi-vessel  disease
have also been published (Table 4). Among cohort studies, the single-stage HCR was most
commonly  employed.  Across  these  studies,  age  averaged  around 60  years  with  a  male
predominance. Left ventricular ejection fraction (LVEF) was preserved or mildly reduced
in  the  majority  of  patients.  With  the  exception  of  data  from  Leacche  et  al.,  overall  in-
hospital mortality, stroke and reoperation for bleeding rates were comparable and low [0%
to 2.6%). The outlier reported by Leacche et al. was among the high SYNTAX-HCR group
with a reported in-hospital mortality of 23% leading the authors to suggest that HCR should
be approached with caution in patients with high (≥33] SYNTAX scores [17]. These reports
collectively suggest that HCR may be a comparable option to CABG in patients with non-
LAD lesions accessible by PCI.
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Author, Year 
Type of Study 
N Surgical Technique Timing of PCI Age, years Male, % LVEF % 
SYNTAX 
Score 
In-Hospital 
Mortality 
Follow-Up 
Period 
Survival 
Shen et al., 2013 
Retrospective, matched cohort 
study 
(propensity matched) 
Recruitment: 2007-2010 (23) 
141 HCR 
141 CABG 
141 PCI 
Lower partial mini-
sternotomy 
CABG (on and off 
pump) 
One Stage 
62±9.9 
62.4±7.8 
61.7±10.3 
88.7 
90.1 
87.2 
62.7±7.1 
62.6±8.0 
62.1± 9.3 
27.6±7.9 
28.2±9.4 
26.0±8.2 
N/A 30 days 
99.3% 
97.2% 
96.5% 
Leacche et al., 2013 
Retrospective cohort study 
(group stratification) 
Recruitment: 2005-2009 (17) 
80 HCR 
SYNTAX≤32 (67) 
SYNTAX>32 (13) 
301 CABG 
SYNTAX≤32 (226) 
SYNTAX>32 (75) 
OP 22% 
OP 31% 
OP 15% 
OP 16% 
One Stage 
62 (32-85) 
74 (32-84) 
63 (32-89) 
62 (32-83) 
79 
62 
75 
83 
50 (20-70) 
50 (20-65) 
55 (10-80) 
50 (10-70) 
N/A **** 30 days N/A 
Bachinsky et al., 2012 
Prospective cohort study, no 
matching 
Recruitment: 2009-2011 (24) 
25 HCR 
27 CABG 
OP MIDCab (Robotic) 
100% 
OP CABG 
(thoracotomy) 
One Stage 
63.2±10.5 
66.78±10.7 
80 
59 
55.3±10.4 
51.48±12.0 
33.52±8 
34.89±8.2 
0% 
4% 
30 days 
100% 
96% 
Halkos et al., 2011 
Retrospective matched cohort 
study 
(propensity matching) 
Recruitment: 2003-2010 (25) 
147 HCR 
588 CABG 
OP EndoACAB 
OP CABG 
Surgery and 
PCI within 2-3 
day (137); One 
stage (10) 
64.3±12.8 
64.3±12.5 
38.1 
28.6 
54.7±8.7 
54.6±8.7 
N/A 
0.7% 
0.9% 
3.2 years 
5-year 
survival: 
86.8% 
84.3% 
Vassiliades et al., 2009 
Retrospective cohort study (no 
matching, 
propensity score adjustment) 
Recruitment: 2003-2007 (26) 
91 HCR 
4175 CABG 
OP EndoACAB 
OP CABG 
85 CABG first 
6 PCI first 
64.7±13.7 
62.8±11.7 
40.7 
37.3 
51.5±9.4 
50.9±12.7 
N/A 
0% 
1.8% 
3 years 
94.0% 
89.2% 
Zhao et al., 2009 
Retrospective cohort study (no 
matching) 
Recruitment: 2005-2007 (27) 
112 HCR 
20 CABG 
Reversed-J inferior 
sternotomy 
OP CABG 
One Stage 
63 (32-85) 
63 (32-89) 
71 
76 
50 (15-70) 
54 (10-72) 
N/A 
2.6% 
1.5% 
N/A N/A 
Reicher et al., 2008 
Prospective, matched cohort 
study 
(propensity matching) 
2005-2006 (28) 
12 HCR 
26 CABG 
OP MidCab 
OP CABG 
(sternotomy) 
CABG first 
62±10 
64±10 
80 
83 
31 (EF <40%) 
27 (EF <40%) 
N/A 
0% 
0% 
30 days 
100% 
100% 
Kon et al., 2008 
Matched prospective cohort 
study, 
unclear matching method 
Recruitment: 2005-2006 (29) 
15 HCR 
30 CABG 
OP MidCab 
OP CABG 
(sternotomy) 
One Stage 
61±10 
65±10 
73 
63 
47±14 
45±14 
N/A 
0% 
0% 
12 mo. 
100% 
100% 
**** see text 
Table 4. Studies Comparing Outcomes After HCR Versus CABG or PCI in the Drug Eluting Stent Era [5, 22]
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Harskamp et al. published a meta-analysis in 2014 reporting clinical outcomes after HCR in
1,190 patients in single-center registries [18]. This study incorporated six observational studies
(one case control and five propensity adjusted) that included adjustments for differences in
baseline characteristics. Comparisons of individual components showed no differences in all-
cause mortality, MI, or stroke at one year follow-up (odds ratio: 0.49; 95% confidence interval:
0.2 -1.24; p=0.13), however the HCR group demonstrated a higher repeat revascularization rate
compared with CABG. These findings were irrespective of the order in which LIMA-LAD graft
and PCI were performed.
The only current randomized control trial comparing HCR and CABG was published in 2014
[19]. Two-hundred consecutive patients from a single institution with angiographically
confirmed multi-vessel disease involving the proximal LAD and a significant (>70%) lesion in
at least one major non-LAD epicardial vessel amenable to both PCI and CABG were random‐
ized in a 1:1 fashion. The primary endpoint was the evaluation of the safety of HCR. The HCR
group (n=98) utilized MIDCAB and cobalt chromium DES with a two-stage HCR with PCI
performed within 36 h of initial MIDCAB, versus the conventional CABG group (n=102) in
which 85.0% of the procedures were performed off-pump. Pre-operative characteristics were
similar. Regarding HCR procedures, 6.1% patients were converted to CABG with no adverse
early or late outcomes, and HCR was feasible in 93.9% of patients. At 1 year, the two groups
had similar all-cause mortality (CABG 2.9% versus HCR 2%; p=NS) and MACE-free survival
rates (CABG 92.2% versus HCR 89.8%; p log-rank =0.54). Larger studies are needed to power
conclusions regarding long-term mortality data; however, this study suggests that HCR is
feasible and safe.
Harskamp et al. recently published a study of practice patterns and clinical outcomes after
HCR, in the United States, using the Society of Thoracic Surgeons Adult Cardiac Surgery
Database from July 2011 to March 2013 [11]. This analysis demonstrated that HCR represented
0.48% (n=950; staged=809, concurrent=141) of the total CABG volume (n=198,622) over the
studied time. HCR was performed in approximately one-third of participating centers (n=361).
Interestingly, patients who underwent HCR had high-risk profiles but less extensive coronary
disease. There was no statistically significant association between operative approach and
operative mortality when comparing the HCR and conventional CABG treatment groups [11].
5. Conclusions
Hybrid coronary revascularization has emerged as a promising technique that combines the
superior patency of the LIMA-LAD graft with the superior patency of DES to SVG grafts for
non-LAD vessels. As with any new technique, ongoing research will benefit from standardized
definitions as well as sub-classification for HCR procedures [20]. Current evidence also lacks
direction as to which patient population benefits most from HCR. Current data supports HCR
as a feasible alternative to CABG, however, the future of these techniques will rely on improved
patient satisfaction, recovery, and financial feasibility. Current reported quality of life assess‐
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ments 1 year post-operatively are remarkably better in patients undergoing HCR versus
OPCAB [5]. Likely reasons include decreased post-operative pain and decreased length of
intensive care and hospital stay with quicker return to work and normal activities. Cost
analysis have been reported both equal and in favor of HCR; however, these analysis did not
examine the hidden cost of construction of a cardiac hybrid operating room as well as training
of personal [5]. Further studies are needed to firmly establish improved outcomes and financial
benefits of HCR before this novel technique establishes itself as a widespread option in the
algorithm of coronary revascularization.
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